Although the prevalence of hyperuricemia is high after renal transplantation, investigation has shown that gout occurs rarely in these patients. The present study was designed to investigate the prevalence of hyperuricemia and gout in renal transplant patients. The records of 155 patients (M/F, 119/36, mean age 34.7±9.7 years) who underwent renal transplantation in between 2000 and 2002 were reevaluated. Patients with at least two years stable graft survival duration were included. For each individual, mean value of serum uric acid levels that were repeated in each routine visits approximately every six months in transplantation clinic were used. Patient demographics, immunosuppressive drug regimens and other medications were also recorded. Hyperuricemia was defined as serum uric acid level of >6.5 mg/dL in females and 7.5 mg/dL in males. Clinical gout was defined as hyperuricemia with gouty arthritis and tophi. Hyperuricemia and gout were seen in 95 patients, and 13 patients, respectively. Mean serum uric acid levels were 8.2±2.3 mg/dL. Increased uric acid levels were found to be independent from patients’ age, sex, donor type, and immunosuppressive drug regimen. Our study confirmed that although hyperuricemia is a common complication in renal transplant recipients, gout is not seen often in these populations.